Parkinson disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• STAT3 0
• TREM2 0
• HDAC 0
• JAK 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

EU-13 is a filter, not a ranking: it only narrows the list.

10 of 10+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

  NCT07348250· Invicro· Updated 27 Jul 2026

  “Study terminated due to site closure.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

  NCT07216066· Regeneron Pharmaceuticals· Source

• Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution

  NCT06941012· Casa di Cura IGEA· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 75
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 34
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 49
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 100
• Magnetic Resonance Imaging 366
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 184
• Genome-Wide Association Study 83

• Differential and directional body coupling analysis in Parkinsonian gait.

  PLoS One, Nov 2026

• Resource allocation under uncertainty and equity constraints in Parkinson's disease care: An econometrically grounded machine learning framework.

  PLoS One, Nov 2026

• Early Detection of Bladder Cancer Using Advanced Feature Engineering and Swarm Intelligence Optimization on EHRs.

  IEEE Trans Biomed Eng, Nov 2026

• Early health technology assessment of machine learning-enabled remote monitoring for advanced Parkinson disease.

  Int J Technol Assess Health Care, Oct 2026

• Identification and experimental validation of candidate biomarkers for Parkinson's Disease through integrated bioinformatics, Mendelian randomization, and machine learning.

  Mol Biol Rep, Oct 2026

• Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis.

  Neurotox Res, Oct 2026

• Cross-species molecular stratification enables T cell receptor diagnosis of Parkinson's disease.

  Genome Med, Sept 2026

• Explicit Mechanistic Causal Analyses or Interventional Trials Are Required for Objective, Clinical, Voice-Based Parkinson Disease Characterization.

  J Med Internet Res, Sept 2026

• From beta thresholds to learned control: machine learning in adaptive deep brain stimulation.

  J Clin Neurosci, Sept 2026

• MIND-based cortical similarity networks reveal distinct cortical alterations in motor subtypes of Parkinson's disease.

  Neuroimage, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.